[Radioiodine therapy for Graves' disease: problems and new developments]

Area of Science:

• Endocrinology
• Nuclear Medicine
• Thyroidology

Context:

• Graves' disease management in Germany often involves radioiodine therapy after other treatments fail or are contraindicated.
• Radioiodine is particularly effective for patients with normal or small thyroid glands, high TSH-receptor antibody titers, and smokers.

Purpose:

• To outline the current guidelines and recommendations for radioiodine therapy in Graves' disease patients in Germany.
• To highlight patient selection criteria, including age, thyroid volume, and specific clinical conditions.
• To discuss the management of potential side effects and drug interactions.

Summary:

• Radioiodine therapy is a preferred treatment for Graves' disease in Germany, especially when antithyroid drugs are ineffective or cause side effects.
• Individual dosimetry is mandatory, and thyroid volume influences the therapeutic activity required.
• Withdrawal of antithyroid drugs before treatment and corticosteroid prophylaxis for Graves' orbitopathy are key considerations.

Impact:

• Radioiodine treatment for Graves' disease is associated with very low risks and high cost-effectiveness.
• The study supports a risk-adapted approach, potentially reducing the need for routine corticosteroid prophylaxis.
• Guidelines emphasize individualized treatment based on patient factors for optimal results.